| Assessment Method | Pre cycle 1 | Post cycle 3 | Post cycle 6 | 2-year follow-up |
---|---|---|---|---|---|
Primary Outcome | |||||
 Target lesion size change after 6 cycles (mm) | CT Scan | X |  | X |  |
Secondary Outcomes | |||||
 Target lesion apparent diffusion coefficient (mm2/s) | MRI | X |  | X |  |
 Target lesion size change after 3 cycles (mm) | CT Scan | X | X |  |  |
Tertiary Outcomes | |||||
 Left ventricular ejection fraction (%) | MRI | X |  | X |  |
 Left ventricular global longitudinal strain (%) | MRI | X |  | X |  |
 Left ventricular mass (g/m2) | MRI | X |  | X |  |
 Liver fat fraction (%) | MRI | X |  | X |  |
 Liver T1 time (ms) | MRI | X |  | X |  |
 Thigh skeletal muscle T1 time (ms) | MRI | X |  | X |  |
 Thigh skeletal muscle volume (mL) | MRI | X |  | X |  |
 Thigh skeletal muscle fat fraction (%) | MRI | X |  | X |  |
 Treatment symptomsa | Rotterdam Symptom Checklist | X | X | X |  |
 Quality of life | FACT-Fatigue Questionnaire | X | X | X |  |
 Fatigue | FACT-Fatigue Questionnaire | X | X | X |  |
Exploratory Outcomes | |||||
 Progression-free survival (months) | Medical records |  |  |  | X |
 Overall survival (months) | Medical records |  |  |  | X |